These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

545 related articles for article (PubMed ID: 30307466)

  • 21. Preoperative concurrent endocrine therapy with chemotherapy in luminal B-like breast cancer.
    Matsunuma R; Watanabe T; Hozumi Y; Koizumi K; Ito Y; Maruyama S; Ogura H; Goto K; Mori H; Sawai N; Shiiya N
    Breast Cancer; 2020 Sep; 27(5):819-827. PubMed ID: 32144735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial.
    Wu W; Chen J; Deng H; Jin L; He Z; Rao N; Nie Y; Yao Y; Yang Y; Su F; Liu J
    BMC Cancer; 2021 Jul; 21(1):862. PubMed ID: 34315439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial.
    Adamo B; Bellet M; Paré L; Pascual T; Vidal M; Pérez Fidalgo JA; Blanch S; Martinez N; Murillo L; Gómez-Pardo P; López-González A; Amillano K; Canes J; Galván P; González-Farré B; González X; Villagrasa P; Ciruelos E; Prat A
    Breast Cancer Res; 2019 Sep; 21(1):108. PubMed ID: 31533777
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
    Wu W; Deng H; Rao N; You N; Yang Y; Cao M; Liu J
    Trials; 2017 Oct; 18(1):497. PubMed ID: 29070044
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.
    Turner NC; Slamon DJ; Ro J; Bondarenko I; Im SA; Masuda N; Colleoni M; DeMichele A; Loi S; Verma S; Iwata H; Harbeck N; Loibl S; André F; Puyana Theall K; Huang X; Giorgetti C; Huang Bartlett C; Cristofanilli M
    N Engl J Med; 2018 Nov; 379(20):1926-1936. PubMed ID: 30345905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study.
    Masuda N; Nishimura R; Takahashi M; Inoue K; Ohno S; Iwata H; Mori Y; Hashigaki S; Muramatsu Y; Nagasawa T; Umeyama Y; Toi M
    Cancer Sci; 2018 Mar; 109(3):803-813. PubMed ID: 29345736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy.
    Varella L; Eziokwu AS; Jia X; Kruse M; Moore HCF; Budd GT; Abraham J; Montero AJ
    Breast Cancer Res Treat; 2019 Jul; 176(2):429-434. PubMed ID: 30895534
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases.
    Turner NC; Finn RS; Martin M; Im SA; DeMichele A; Ettl J; Diéras V; Moulder S; Lipatov O; Colleoni M; Cristofanilli M; Lu DR; Mori A; Giorgetti C; Iyer S; Bartlett CH; Gelmon KA
    Ann Oncol; 2018 Mar; 29(3):669-680. PubMed ID: 29342248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
    Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
    Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial.
    Dellapasqua S; Gray KP; Munzone E; Rubino D; Gianni L; Johansson H; Viale G; Ribi K; Bernhard J; Kammler R; Maibach R; Rabaglio-Poretti M; Ruepp B; Di Leo A; Coates AS; Gelber RD; Regan MM; Goldhirsch A; Colleoni M;
    J Clin Oncol; 2019 Feb; 37(5):386-395. PubMed ID: 30589600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response and Prognosis of Docetaxel and Cyclophosphamide as Neoadjuvant Chemotherapy in ER
    Hayashi N; Yagata H; Tsugawa K; Kajiura Y; Yoshida A; Takei J; Yamauchi H; Nakamura S
    Clin Breast Cancer; 2020 Dec; 20(6):462-468. PubMed ID: 33046356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expanded-Access Study of Palbociclib in Combination With Letrozole for Treatment of Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer.
    Stearns V; Brufsky AM; Verma S; Cotter MJ; Lu DR; Dequen F; Joy AA
    Clin Breast Cancer; 2018 Dec; 18(6):e1239-e1245. PubMed ID: 30172722
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval.
    Kish JK; Ward MA; Garofalo D; Ahmed HV; McRoy L; Laney J; Zanotti G; Braverman J; Yu H; Feinberg BA
    Breast Cancer Res; 2018 May; 20(1):37. PubMed ID: 29720233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer.
    Gonçalves A; Pierga JY; Ferrero JM; Mouret-Reynier MA; Bachelot T; Delva R; Fabbro M; Lerebours F; Lotz JP; Linassier C; Dohollou N; Eymard JC; Leduc B; Lemonnier J; Martin AL; Boher JM; Viens P; Roché H
    Ann Oncol; 2015 Aug; 26(8):1692-7. PubMed ID: 25943350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer.
    Yuan Y; Lee JS; Yost SE; Frankel PH; Ruel C; Egelston CA; Guo W; Padam S; Tang A; Martinez N; Schmolze D; Presant C; Ebrahimi B; Yeon C; Sedrak M; Patel N; Portnow J; Lee P; Mortimer J
    Eur J Cancer; 2021 Sep; 154():11-20. PubMed ID: 34217908
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial.
    Diéras V; Harbeck N; Joy AA; Gelmon K; Ettl J; Verma S; Lu DR; Gauthier E; Schnell P; Mori A; Rugo HS; Finn RS
    Oncologist; 2019 Dec; 24(12):1514-1525. PubMed ID: 31217344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
    Bagegni N; Thomas S; Liu N; Luo J; Hoog J; Northfelt DW; Goetz MP; Forero A; Bergqvist M; Karen J; Neumüller M; Suh EM; Guo Z; Vij K; Sanati S; Ellis M; Ma CX
    Breast Cancer Res; 2017 Nov; 19(1):123. PubMed ID: 29162134
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Primary results from PALOMA-4.
    Xu B; Hu X; Li W; Sun T; Shen K; Wang S; Cheng Y; Zhang Q; Cui S; Tong Z; Geng C; Song E; Huang CS; Sriuranpong V; Ngan RKC; Chia YH; Wang X; Zhao H
    Eur J Cancer; 2022 Nov; 175():236-245. PubMed ID: 36155117
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.
    Pritchard KI; Chia SK; Simmons C; McLeod D; Paterson A; Provencher L; Rayson D
    Oncologist; 2017 Jan; 22(1):12-24. PubMed ID: 27864574
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Time to treatment failure of palbociclib and letrozole as second-line therapy or beyond in hormone receptor-positive advanced breast cancer.
    Schickli MA; Berger MJ; Lustberg M; Palettas M; Vargo CA
    J Oncol Pharm Pract; 2019 Sep; 25(6):1374-1380. PubMed ID: 30134767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.